ES2530815T3 - Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas - Google Patents
Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas Download PDFInfo
- Publication number
- ES2530815T3 ES2530815T3 ES09767711T ES09767711T ES2530815T3 ES 2530815 T3 ES2530815 T3 ES 2530815T3 ES 09767711 T ES09767711 T ES 09767711T ES 09767711 T ES09767711 T ES 09767711T ES 2530815 T3 ES2530815 T3 ES 2530815T3
- Authority
- ES
- Spain
- Prior art keywords
- independently selected
- cycloalkyl
- alkenyl
- alkoxy
- hydroxyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuesto de fórmula I:**Fórmula** en la que: X es alquileno C1-C9, alquenileno C2-C9 o alquinileno C2-C9; Y es O o S; R1, R2, R3 y R4 se seleccionan independientemente de hidrógeno, halógeno, hidroxilo, NH2, alcoxilo C1-C6, CN, perfluoroalquilo C1-C6; R5 y R6 son cada uno, independientemente, hidrógeno, alquilo C1-C6, alquenilo C2-C4, cicloalquilo C3-C7, fenilo o bencilo, en los que el alquilo, el alquenilo y los anillos de los grupos cicloalquilo, fenilo y bencilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de hidroxilo, alcoxilo C1-C4, -CO2H, alcoxi C1-C6-carbonilo, NH2, mono o dialquilamino C1-C6 o halógeno; o R5 y R6 junto con el nitrógeno al que están unidos forman un anillo heterocíclico, monocíclico o bicíclico, de 3 a 12 miembros, saturado, parcialmente insaturado o insaturado, que comprende opcionalmente desde uno hasta tres heteroátomos de anillo adicionales seleccionados independientemente de N, O o S, siendo el resto de los átomos de anillo átomos de carbono; o una forma de sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7385708P | 2008-06-19 | 2008-06-19 | |
PCT/US2009/047767 WO2009155402A1 (en) | 2008-06-19 | 2009-06-18 | Thiazolyl- and oxazolyl-isoquinolinones and methods for using them |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2530815T3 true ES2530815T3 (es) | 2015-03-05 |
Family
ID=41087350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09767711T Active ES2530815T3 (es) | 2008-06-19 | 2009-06-18 | Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas |
Country Status (12)
Country | Link |
---|---|
US (3) | US8299090B2 (es) |
EP (2) | EP2303895B1 (es) |
JP (2) | JP5564495B2 (es) |
AR (1) | AR072265A1 (es) |
AU (1) | AU2009260060B2 (es) |
CA (1) | CA2728454C (es) |
DK (1) | DK2303895T3 (es) |
ES (1) | ES2530815T3 (es) |
HK (2) | HK1156310A1 (es) |
SA (1) | SA109300394B1 (es) |
TW (1) | TWI471329B (es) |
WO (1) | WO2009155402A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA109300394B1 (ar) * | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
CA2728466A1 (en) | 2008-06-19 | 2009-12-23 | Wyeth Llc | Thienyl- and furanyl-isoquinolinones and methods for using them |
JP2014520776A (ja) | 2011-07-04 | 2014-08-25 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 植物における非生物的ストレスに対する活性薬剤としての置換されているイソキノリノン類、イソキノリンジオン類、イソキノリントリオン類およびジヒドロイソキノリノン類または各場合でのそれらの塩の使用 |
EP2733144B1 (en) * | 2011-07-13 | 2016-01-06 | Santen Pharmaceutical Co., Ltd | Novel compound having parp inhibitory activity |
DK3594343T3 (da) | 2015-07-23 | 2021-06-28 | Inst Curie | Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005745B1 (en) * | 1978-05-26 | 1982-07-14 | Gruppo Lepetit S.P.A. | Pyrazolo (3,4-c) and thiazolo (5,4-c) isoquinolines, methods for preparing them, these compounds for use as antiinflammatory, cns-depressant and anti-anxiety agents and pharmaceutical compositions thereof |
ITMI20002358A1 (it) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
ES2376166T3 (es) | 2002-11-22 | 2012-03-09 | Mitsubishi Tanabe Pharma Corporation | Compuestos de isoquinolina y su uso medicinal. |
US7696255B2 (en) | 2005-08-01 | 2010-04-13 | Wietek Holding Gmbh | Process for the recycling of plastics |
CN101506214A (zh) * | 2006-06-20 | 2009-08-12 | 艾博特公司 | 作为parp抑制剂的吡唑并喹唑啉酮 |
SA109300394B1 (ar) * | 2008-06-19 | 2013-01-22 | ويث | ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها |
CA2728466A1 (en) | 2008-06-19 | 2009-12-23 | Wyeth Llc | Thienyl- and furanyl-isoquinolinones and methods for using them |
-
2009
- 2009-06-17 SA SA109300394A patent/SA109300394B1/ar unknown
- 2009-06-18 WO PCT/US2009/047767 patent/WO2009155402A1/en active Application Filing
- 2009-06-18 ES ES09767711T patent/ES2530815T3/es active Active
- 2009-06-18 EP EP09767711.6A patent/EP2303895B1/en active Active
- 2009-06-18 AU AU2009260060A patent/AU2009260060B2/en active Active
- 2009-06-18 EP EP14185672.4A patent/EP2896626A1/en not_active Withdrawn
- 2009-06-18 CA CA2728454A patent/CA2728454C/en active Active
- 2009-06-18 DK DK09767711.6T patent/DK2303895T3/en active
- 2009-06-18 US US12/487,247 patent/US8299090B2/en active Active
- 2009-06-18 JP JP2011514801A patent/JP5564495B2/ja not_active Expired - Fee Related
- 2009-06-19 AR ARP090102266A patent/AR072265A1/es active IP Right Grant
- 2009-06-19 TW TW98120713A patent/TWI471329B/zh active
-
2011
- 2011-10-06 HK HK11110561.5A patent/HK1156310A1/xx unknown
-
2012
- 2012-10-18 US US13/655,082 patent/US8906935B2/en active Active
-
2014
- 2014-03-28 JP JP2014067493A patent/JP2014122242A/ja not_active Withdrawn
- 2014-11-07 US US14/535,877 patent/US9265769B2/en active Active
-
2016
- 2016-01-21 HK HK16100665.6A patent/HK1212698A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA2728454C (en) | 2017-01-17 |
HK1212698A1 (zh) | 2016-06-17 |
AU2009260060A1 (en) | 2009-12-23 |
US8906935B2 (en) | 2014-12-09 |
US20150133443A1 (en) | 2015-05-14 |
AR072265A1 (es) | 2010-08-18 |
US20130059843A1 (en) | 2013-03-07 |
EP2896626A1 (en) | 2015-07-22 |
JP2014122242A (ja) | 2014-07-03 |
SA109300394B1 (ar) | 2013-01-22 |
AU2009260060B2 (en) | 2015-01-22 |
JP5564495B2 (ja) | 2014-07-30 |
DK2303895T3 (en) | 2015-01-12 |
EP2303895B1 (en) | 2014-09-24 |
US9265769B2 (en) | 2016-02-23 |
TW201002725A (en) | 2010-01-16 |
US20090318442A1 (en) | 2009-12-24 |
US8299090B2 (en) | 2012-10-30 |
TWI471329B (zh) | 2015-02-01 |
JP2011525185A (ja) | 2011-09-15 |
CA2728454A1 (en) | 2009-12-23 |
WO2009155402A1 (en) | 2009-12-23 |
HK1156310A1 (en) | 2012-06-08 |
EP2303895A1 (en) | 2011-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2530815T3 (es) | Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas | |
AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
AR086367A1 (es) | Compuestos de pirrolidinil urea y pirrolidinil tiourea como inhibidores de cinasa trka | |
PE20090060A1 (es) | ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR | |
PE20150400A1 (es) | Benzamidas n-sustituidas y su uso en el tratamiento del dolor | |
PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
AR082154A1 (es) | DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4 | |
AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
CO6300939A2 (es) | Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada | |
EA201200390A1 (ru) | Макроциклические ингибиторы сериновых протеаз гепатита с | |
AR068503A1 (es) | Derivados de amidas sustituidas, composicion farmaceutica y usos. | |
AR061238A1 (es) | Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c | |
ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
NI201000119A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis. | |
AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
AR074306A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes | |
CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico |